Increased risk of neutropaenia and agranulocytosis with sodium valproate used adjunctively with clozapine [6]

Australian and New Zealand Journal of Psychiatry

Volumn 35, Issue 4, 2001, Pages 544-545

  Pantelis, C ^a   Adesanya, A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CARBAMAZEPINE; CLOZAPINE; NEUROLEPTIC AGENT; VALPROIC ACID;

ADULT; AFFECTIVE NEUROSIS; AGRANULOCYTOSIS; BEHAVIOR DISORDER; CASE REPORT; DELUSION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HALLUCINATION; HOSPITALIZATION; HUMAN; HYPERSALIVATION; INCIDENCE; LETTER; LEUKOCYTE COUNT; LEUKOPENIA; NEUTROPENIA; PATIENT COMPLIANCE; RELAPSE; RISK ASSESSMENT; SCHIZOPHRENIA; SEXUAL DYSFUNCTION;

ADULT; AGRANULOCYTOSIS; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; NEUTROPENIA; RISK FACTORS; SCHIZOPHRENIA; VALPROIC ACID;

EID: 0034856674     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1614.2001.0911f.x     Document Type: Letter

References (5)

1. Drug strategies and treatment-resistant schizophrenia
2. Clozapine treatment in Australia: A review of haematological monitoring
3. A review of cyclic antidepressant-induced blood dyscrasias
4. Concurrent use of clozapine and valproate in affective and psychotic disorders
5. Serum concentrations of clozapine and its major metabolites: Effects of cotreatment with fluoxetine or valproate